Home / Asia-Pacific / China / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 480 lawyers, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

07/06/2022
Trade secret laws and reg­u­la­tions in China
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
31/05/2022
Over­view of Loc­al­iz­a­tion Trend of Med­ic­al Devices
On 21 April 2022, the De­part­ment of Fin­ance of An­hui Province, the Health Com­mis­sion of An­hui Province and the Health­care Se­cur­ity Bur­eau of An­hui Province jointly is­sued the Cir­cu­lar on Reg­u­lat­ing Gov­ern­ment...
30/05/2022
Over­view of Loc­al­iz­a­tion Trend of Med­ic­al Devices
On 21 April 2022, the De­part­ment of Fin­ance of An­hui Province, the Health Com­mis­sion of An­hui Province and the Health­care Se­cur­ity Bur­eau of An­hui Province jointly is­sued the Cir­cu­lar on Reg­u­lat­ing Gov­ern­ment...
16/05/2022
High­lights on Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing
The Na­tion­al Med­ic­al Products Ad­min­is­tra­tion ("NMPA") is­sued the Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing (“Pro­vi­sions”) on 11 April 2022, which took ef­fect on the same day. The Pro­vi­sions...
13/05/2022
High­lights on Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing
The Na­tion­al Med­ic­al Products Ad­min­is­tra­tion ("NMPA") is­sued the Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing (“Pro­vi­sions”) on 11 April 2022, which took ef­fect on the same day.The Pro­vi­sions...
29/04/2022
New Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Trad­ing
The Na­tion­al Mar­ket Su­per­vi­sion Ad­min­is­tra­tion ad­op­ted the Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Trad­ing (“Meas­ures”) on 10 March 2022, which will take ef­fect as of 1 May...
29/04/2022
New Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing
The Na­tion­al Mar­ket Su­per­vi­sion Ad­min­is­tra­tion ad­op­ted the Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing (“Meas­ures”) on 10 March 2022, which will take ef­fect as...
29/04/2022
New Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing
The Na­tion­al Mar­ket Su­per­vi­sion Ad­min­is­tra­tion ad­op­ted the Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing (“Meas­ures”) on 10 March 2022, which will take ef­fect as...
28/04/2022
New Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Trad­ing
The Na­tion­al Mar­ket Su­per­vi­sion Ad­min­is­tra­tion ad­op­ted the Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Trad­ing (“Meas­ures”) on 10 March 2022, which will take ef­fect as of 1...
26/04/2022
New Med­ic­al Devices Good Clin­ic­al Prac­tice
The Na­tion­al Med­ic­al Products Ad­min­is­tra­tion ("NMPA") pro­mul­gated the newly re­vised Med­ic­al Devices Good Clin­ic­al Prac­tice ("New GCP Stand­ard") on 31 March 2022. This New GCP Stand­ard will enter in­to...
25/04/2022
New Med­ic­al Devices Good Clin­ic­al Prac­tice
The Na­tion­al Med­ic­al Products Ad­min­is­tra­tion ("NMPA") pro­mul­gated the newly re­vised Med­ic­al Devices Good Clin­ic­al Prac­tice ("New GCP Stand­ard") on 31 March 2022. This New GCP Stand­ard will enter in­to...